Annuncio • Mar 13
MEDICOX Co., Ltd., Annual General Meeting, Mar 31, 2026 MEDICOX Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7, nonhyeon-ro 64-gil, gangnam-gu, seoul South Korea New Risk • Jun 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.3b (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Market cap is less than US$10m (₩13.3b market cap, or US$9.76m). New Risk • May 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩22.3b market cap, or US$16.2m). New Risk • Apr 28
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.8b (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Market cap is less than US$10m (₩13.8b market cap, or US$9.59m). Annuncio • Mar 18
MEDICOX Co., Ltd., Annual General Meeting, Mar 31, 2025 MEDICOX Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 26, apgujeong-ro 79-gil, gangnam-gu, seoul South Korea New Risk • Mar 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩20.4b market cap, or US$14.0m). New Risk • Jan 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩21.6b market cap, or US$14.8m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩19.0b market cap, or US$13.2m). New Risk • Dec 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩11b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩18.1b market cap, or US$12.6m). New Risk • Dec 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩11b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩19.5b market cap, or US$14.0m). New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩25.7b market cap, or US$19.5m). Annuncio • Jul 16
MEDICOX Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999585 million. MEDICOX Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999585 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,727,115
Price\Range: KRW 579
Transaction Features: Subsequent Direct Listing Annuncio • Jul 05
MEDICOX Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.999585 million. MEDICOX Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.999585 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,727,115
Price\Range: KRW 579
Transaction Features: Subsequent Direct Listing New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩36.3b market cap, or US$26.3m). Reported Earnings • Mar 26
Full year 2023 earnings released: ₩1,004 loss per share (vs ₩1,979 loss in FY 2022) Full year 2023 results: ₩1,004 loss per share (improved from ₩1,979 loss in FY 2022). Revenue: ₩26.9b (up 32% from FY 2022). Net loss: ₩29.1b (loss narrowed 30% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings. New Risk • Nov 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 53% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩38.2b market cap, or US$29.0m). New Risk • Jun 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩47.3b market cap, or US$36.5m). Annuncio • May 11
MEDICOX Co., Ltd. announced that it has received KRW 3.99999852 billion in funding On May 10, 2023, MEDICOX Co., Ltd. closed the transaction. Annuncio • Feb 08
MEDICOX Co., Ltd. announced that it expects to receive KRW 17.999998883 billion in funding from Guwol Partners Co. , Ltd. MEDICOX Co., Ltd. announced a private placement of 9,830,693 shares at an issue price of KRW 1,831 per share for a gross proceeds of KRW 17,999,998,883 on February 7, 2023. The transaction will include participation from new investor, Guwol Partners Co. , Ltd. for 9,830,693 shares. The company issued shares through third party allocation method. The transaction is expected to close on February 16, 2023. The transaction has been approved by the board of directors of the company. Annuncio • Jan 28
MEDICOX Co., Ltd. announced that it expects to receive KRW 999.99738 million in funding from Nowinvestment. Co. Ltd, Cereal Co., Ltd. MEDICOX Co., Ltd. announced that it will issue 520,290 common shares of par value, KRW 500 at a price of KRW 1,922 per share for gross proceeds of KRW 999,997,380 on January 27, 2023. The transaction will include participation from returning investor Nowinvestment. Co. Ltd, and Cereal Co., Ltd for 260,145 shares each. The company will issue shares through third party allocation increase. The payment date for shares is February 28, 2023. The transaction has been approved by board of directors of the company. The total number of shares issued prior to transaction are 25,547,329 shares. Annuncio • Dec 22
MEDICOX Co., Ltd. announced that it expects to receive KRW 9.9999977 billion in funding MEDICOX Co., Ltd. announced a private placement of 3,442,340 common shares at an issue price of KRW 2,905 for the gross proceeds of KRW 9,999,997,700 on December 20, 2022. The transaction will include participation from TSI Investment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on February 20, 2023. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jul 15
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Apr 22
MEDICOX Co., Ltd. announced that it has received KRW 5 billion in funding from Sangsangin Savings Bank, Investment Arm On April 20, 2022, MEDICOX Co., Ltd. closed the transaction. Annuncio • Feb 11
An unknown buyer agreed to acquire 5.99% stake in Connec Co. Ltd. from MEDICOX Co., Ltd. (KOSDAQ:A054180) for KRW 11.2 billion. An unknown buyer entered into a share and management right transfer agreement to acquire 5.99% stake in Connec Co. Ltd. from MEDICOX Co., Ltd. (KOSDAQ:A054180) for KRW 11.2 billion on December 23, 2021. Payment schedule and payment conditions at Date of signing this contract: Down payment of KRW 1.1 billion, February 09, 2022: Payment of KRW 1 billion and February 28, 2022: Balance of payment of KRW 9 billion. After the conclusion of the contract, at the extraordinary general meeting of shareholders scheduled for February 10, 2022, a registered director recommended by Connec Co. is scheduled to be appointed. The documents related to resignation of all directors currently registered by the day before the extraordinary general meeting of shareholders are submitted to LINK or to be submitted to MEDICOX Co. Annuncio • Jun 05
MEDICOX Co., Ltd. announced that it has received KRW 20 billion in funding from Baro Savings Bank, Sangsangin Plus Savings Bank, Investment Arm, Sangsangin Savings Bank, Investment Arm On June 4, 2021, MEDICOX Co., Ltd. (KOSDAQ:A054180) closed the transaction. Annuncio • Jun 03
MEDICOX Co., Ltd. announced that it expects to receive KRW 20 billion in funding from Baro Savings Bank, Sangsangin Plus Savings Bank, Investment Arm, Sangsangin Savings Bank, Investment Arm MEDICOX Co., Ltd. (KOSDAQ:A054180) announced a private placement of series 17 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on June 2, 2021. The transaction will include participation from Baro Savings Bank for KRW 8,000,000,000, Sangsangin Plus Savings Bank, Investment Arm for KRW 3,000,000,000 and Sangsangin Savings Bank, Investment Arm for KRW 9,000,000,000. The company is raising funding through third party allocation method. The bonds will carry coupon rate of 3% and yield to maturity of 5%, and will mature on June 04, 2024. The bonds will be 100% convertible into 14,336,917 common shares of the company, for 21.97% stake in he company, at a fixed conversion price of KRW 1,395 per share with conversion period from June 04, 2022 to May 04, 2024. The bonds will have a hold period of one year post issuance. The subscription date is June 02, 2021 and the payment date is June 04, 2021. The board of directors of the company approved the transaction. Reported Earnings • Mar 11
Full year 2020 earnings released: ₩248 loss per share (vs ₩135 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩16.2b (down 27% from FY 2019). Net loss: ₩8.58b (loss widened 139% from FY 2019). Is New 90 Day High Low • Feb 03
New 90-day low: ₩1,465 The company is down 31% from its price of ₩2,120 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₩1,490 The company is down 40% from its price of ₩2,480 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 03
New 90-day low: ₩1,660 The company is down 5.0% from its price of ₩1,745 on 04 September 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 16% over the same period. Is New 90 Day High Low • Oct 06
New 90-day high: ₩3,045 The company is up 124% from its price of ₩1,360 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 5.0% over the same period. Annuncio • Sep 22
MEDICOX Co., Ltd. announced that it expects to receive KRW 5 billion in funding ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) announced a private placement of 16th series unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on September 21, 2020. The company is raising funding through third party allocation method. The transaction will include participation from Golden Cloud Fund 1 for KRW 5,000,000,000. The bonds will carry coupon rate of 1% and interest rate of 3%, maturity date will be October 20, 2023. The bonds will be 100% convertible into 2,572,016 common shares of the company at a fixed conversion price of KRW 1944 per share with conversion period from October 20, 2021 to September 20, 2023. The payment date of the transaction is October 20, 2020. The securities in the transaction have a hold period of one year. The place of conversion is at Hana Bank Securities Agency. The board of directors of the company approved the transaction. Annuncio • Sep 04
ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) acquired an additional 21.4% stake in Mecox Curemed Co., Ltd. from Jung, Jae Yong and K Clavis Meister New Technology Association No. Sixty for KRW 12.1 billion. ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) agreed to acquire an additional 21.4% stake in Mecox Curemed Co., Ltd. from Jung Jae Yong and K Clavis Meister New Technology Association No. Sixty for KRW 12.1 billion on August 28, 2020. As part of the consideration, ChoongAng Ocean will issue convertible bonds of 7.1 billion and cash consideration of 4.99 billion. Jung Jae Yong will transfer 0.83 million shares for KRW 5 billion convertible bond and KRW 4.99 billion cash payment and K Clavis Meister New Technology Association No. Sixty sold 0.175 million shares for KRW 2.1 billion convertible bond The board of ChoongAng Ocean passed the resolution on August 28, 2020.
ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) completed the acquisition of an additional 21.4% stake in Mecox Curemed Co., Ltd. from Jung Jae Yong and K Clavis Meister New Technology Association No. Sixty on August 28, 2020. Annuncio • Sep 01
ChoongAng Ocean Co., Ltd. announced that it has received KRW 12.099999764 billion in funding On August 28, 2020, ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) closed the transaction. The company issued 15th series unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 7,100,000,000 in its second tranche. Annuncio • Aug 06
ChoongAng Ocean Co., Ltd. announced that it expects to receive KRW 12.099999764 billion in funding ChoongAng Ocean Co., Ltd. (KOSDAQ:A054180) announced a private placement of 15th series unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 7,100,000,000 and 4,863,813 common shares at a price of KRW 1,028 for gross proceeds of KRW 4,999,999,764, aggregate gross proceeds of KRW 12,099,999,764 on August 5, 2020. The company is raising funding through third party allocation method. The transaction will include participation from new investors Jaeyong Jung for KRW 5,000,000,000 and KCLAVIS Meister New Technology Fund No. 60 for KRW 2,100,000,000, Mecox Biomed Co., Ltd for 4,863,813 shares. The bonds will carry no coupon and maturity date will be August 28, 2023. The bonds will be 100% convertible into 5956375 common shares of the company at a fixed conversion price of KRW 1192 per share with conversion period from August 28, 2021 to July 28, 2023. The payment date of bonds will be August 28, 2020 and of common shares will be August 27, 2020. The shares issued in the transaction have a hold period of one year. The board of directors of the company approved the transaction. Annuncio • Jul 17
ChoongAng Ocean Co., Ltd. announced that it has received KRW 15.996 billion in funding from Seagate Co., Ltd., New Company Co., Ltd. On July 8, 2020, ChoongAng Ocean Co., Ltd. closed the transaction. The company received KRW 9,996,000,000 in its second and final tranche. 
